Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
VSTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.10 - $13.52
Previous CloseN/A
Volume547.29K
Average Volume (3M)749.08K
Market Cap
$342.39M
Enterprise Value$205.26M
Total Cash (Recent Filing)$91.53M
Total Debt (Recent Filing)$125.98M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 08, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.49
Shares Outstanding51,486,706
10 Day Avg. Volume822,384
30 Day Avg. Volume749,076
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.60
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.31K
Enterprise Value/Ebitda-1.99
Forecast
1Y Price Target
$13.20Price Target Upside98.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Verastem News
PremiumCompany Announcements
Verastem Unveils Strategic Plans in New Presentation
PremiumCompany Announcements
Verastem Expands Oncology Pipeline with VS-7375 Acquisition---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe updated Phase 2 RAMP 201 study data for avutometinib and defactinib in recurrent low-grade serous ovarian cancer show an overall response rate of 31%, which is an improvement from previous data and better than current standard-of-care treatments.
Financial StabilityRecent debt refinancing and new credit facilities are seen positively, as they improve VSTM's financial stability and extend its cash runway.
Regulatory ProgressThe FDA acceptance of the new drug application for the combination of avutometinib and defactinib for low-grade serous ovarian cancer is seen as a key milestone for Verastem Inc.
Bears Say
Limited Approval ScopeThe company will initially seek approval only in KRAS-mutant patients, which may limit market potential in the broader population.
Market ReactionVSTM shares are down approximately 20% due to the news that the company will initially seek approval only in KRAS-mutant patients, not KRAS-wild-type patients.
Regulatory ChallengesVerastem Inc shares fell 20% due to market disappointment over a regulatory update limiting initial approval to a subset of patients.
---
Ownership Overview
1.40% Insiders
7.35% Mutual Funds
42.49% Other Institutional Investors
39.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $2.10 and its highest was $13.52 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $342.39M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is May 08, 2025 which is in 46 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Mar 20, 2025. The company reported -$1.33 earnings per share for the quarter, missing the consensus estimate of -$0.829 by -$0.501.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.66.
How many shares outstanding does Verastem have?
Verastem has 51,486,706 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$1.33 in its last earnings report, missing expectations of -$0.829. Following the earnings report the stock price went down -2.493%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in VSTM
---
Verastem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.20 (98.50% Upside)
$13.20 (98.50% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 723.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $58.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 8.9%
Last 30 Days ▼ 8.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.25%
12-Months-Change
Fundamentals
Return on Equity
-526.33%
Trailing 12-Months
Asset Growth
-32.18%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
---
VSTM Stock 12 Month Forecast
Average Price Target
$13.20
▲(98.50% Upside)
Technical Analysis
Best Analysts Covering VSTM
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+17.20%
reiterated a buy rating 3 days ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +17.20% per trade.
---